Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

By E. Mössner, P. Brünker, S. Moser, Ursula Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, Adam Nopora, E. van Puijenbroek and 15 more. Blood, 2010

976 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/155539bd325ae1acbf49d3deef28ec1e0303e80b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Chan
2. P. Carter

In Oncology

1. A. Chan
2. I. Waldhauer
3. P. Carter

In Radiology, Nuclear Medicine and Imaging

1. A. Chan
2. P. Carter

Citations in the corpus

• Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose (2011, background): “Cartron G, et al. (2010) Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients—”
• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “For example, GA-101 (Roche/GlycArt) is a humanized type II CD20-specific antibody that is glyco-engineered (bisected and non-fucosylated) to enhance ADCC and is in Phase II clinical trials for non-Hodgkin's lymphom”
• Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “Neutropenia 84 (35) 18 (16) 60 (27) 18 (16) 111 (33) 91 (28)”